/ALEC
ALEC Stock - Alector, Inc.
Healthcare|BiotechnologyNASDAQ
$1.40+0.72%
+$0.01 (+0.72%) • Dec 19
66
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.9
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.93
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+132.1%upside
Target: $3.25
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ALEC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.39 – $1.41
TARGET (TP)$3.25
STOP LOSS$1.29
RISK/REWARD1:16.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.67
52W High$3.40
52W Low$0.87
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $100.56M | $97.06M | $133.62M | $207.09M | $21.10M |
| Gross Profit | $100.56M | $88.21M | $133.62M | $17.68M | $-135,771,000 |
| Gross Margin | 100.0% | 90.9% | 100.0% | 8.5% | -643.5% |
| Operating Income | $-144,997,000 | $-151,740,000 | $-137,834,000 | $-37,360,000 | $-195,174,000 |
| Net Income | $-119,049,000 | $-130,391,000 | $-133,310,000 | $-36,329,000 | $-190,228,000 |
| Net Margin | -118.4% | -134.3% | -99.8% | -17.5% | -901.6% |
| EPS | $-1.23 | $-1.56 | $-1.62 | $-0.45 | $-2.45 |
Company Overview
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
31%
Hold / Neutral
8
50%
Sell / Underperform
3
19%
Analyst Consensus🔴 Bearish
5 Bullish11 Neutral/Bearish
Price Targets
$8
Average Target
↑ 450.0% Upside
Now
$1
Low
$8
Average
$15
High
Based on 15 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 22nd 2025 | Mizuho | Downgrade | Neutral | $1.5 |
| October 22nd 2025 | TD Cowen | Downgrade | Hold | - |
| October 22nd 2025 | Cantor Fitzgerald | Downgrade | Neutral | - |
| October 22nd 2025 | William Blair | Downgrade | Market Perform | - |
| October 22nd 2025 | BTIG Research | Downgrade | Neutral | - |
| July 28th 2025 | Mizuho | Upgrade | Outperform | $3.5 |
| December 17th 2024 | Mizuho | Downgrade | Neutral | $2.5← $9 |
| December 16th 2024 | Stifel | Downgrade | Hold | $4 |
| December 4th 2024 | BofA Securities | Downgrade | Underperform | $1← $9 |
| November 29th 2024 | H.C. Wainwright | Reiterated | Buy | $7← $35 |
| November 26th 2024 | Morgan Stanley | Downgrade | Underweight | $3← $10 |
| December 14th 2023 | Stifel | Upgrade | Buy | $15← $8 |
| December 12th 2023 | Deutsche Bank | Initiation | Buy | $12 |
| September 25th 2023 | Goldman | Initiation | Sell | $4 |
| September 22nd 2023 | Cantor Fitzgerald | Initiation | Overweight | $13 |
Earnings History & Surprises
ALECBeat Rate
67%
Last 18 quarters
Avg Surprise
-12.2%
EPS vs Estimate
Beats / Misses
12/5
1 met exactly
Latest EPS
$-0.34
Q4 2025
EPS Surprise History
Q1 24
+38.8%
$-0.49vs$-0.80
Q2 24
+20.8%
$-0.38vs$-0.48
Q3 24
+18.4%
$-0.40vs$-0.49
Q4 24
+18.9%
$-0.43vs$-0.53
Q1 25
+96.7%
$-0.02vs$-0.61
Q2 25
+6.8%
$-0.41vs$-0.44
Q3 25
+33.3%
$-0.30vs$-0.45
Q4 25
+19.0%
$-0.34vs$-0.42
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $-0.40 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.42 | $-0.34 | +19.0% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.45 | $-0.30 | +33.3% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.44 | $-0.41 | +6.8% | ✓ BEAT |
Q1 2025 | Feb 26, 2025 | $-0.61 | $-0.02 | +96.7% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $-0.53 | $-0.43 | +18.9% | ✓ BEAT |
Q3 2024 | Aug 7, 2024 | $-0.49 | $-0.40 | +18.4% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-0.48 | $-0.38 | +20.8% | ✓ BEAT |
Q1 2024 | Feb 27, 2024 | $-0.80 | $-0.49 | +38.8% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-0.65 | $-0.53 | +18.5% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-0.82 | $0.02 | +102.4% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $-0.75 | $-0.55 | +26.7% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $-0.54 | $-0.63 | -16.7% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-0.43 | $-0.56 | -30.2% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $-0.47 | $0.12 | +125.5% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $0.37 | $-0.54 | -245.9% | ✗ MISS |
Q1 2022 | Feb 24, 2022 | $-0.13 | $-0.68 | -423.1% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $2.09 | $1.49 | -28.7% | ✗ MISS |
Q3 2021 | Aug 3, 2021 | $-0.69 | $-0.69 | 0.0% | = MET |
Latest News
Alector Appointed Neil Berkley As Chief Financial Officer And Chief Business Officer, Effective Dec. 10
➖ NeutralBenzinga•Dec 12, 2025, 09:07 PM
Alector Affirms FY2025 Sales Guidance of $13.000M-$18.000M vs $16.343M Est
➖ NeutralBenzinga•Nov 6, 2025, 09:37 PM
Alector Q3 EPS $(0.34) Beats $(0.42) Estimate, Sales $3.260M Beat $3.020M Estimate
📈 PositiveBenzinga•Nov 6, 2025, 09:33 PM
TD Cowen Downgrades Alector to Hold
📉 NegativeBenzinga•Oct 22, 2025, 03:12 PM
Cantor Fitzgerald Downgrades Alector to Neutral
📉 NegativeBenzinga•Oct 22, 2025, 03:02 PM
HC Wainwright & Co. Maintains Buy on Alector, Lowers Price Target to $5
➖ NeutralBenzinga•Oct 22, 2025, 02:39 PM
Alector shares are trading lower after the company announced it will discontinue the open-label extension for Latozinemab and reduce its workforce by about 49%.
📉 NegativeBenzinga•Oct 22, 2025, 11:42 AM
William Blair Downgrades Alector to Market Perform
📉 NegativeBenzinga•Oct 22, 2025, 11:28 AM
BTIG Downgrades Alector to Neutral
➖ NeutralBenzinga•Oct 22, 2025, 11:06 AM
Alector slumps on late-stage trial setback for GSK-partnered dementia candidate
📉 NegativeSeeking Alpha•Oct 22, 2025, 10:57 AM•Also:
Alector shares are trading lower after the company announced it will discontinue the open-label extension for Latozinemab and reduce its workforce by about 49%.
📉 NegativeBenzinga•Oct 21, 2025, 08:43 PM
Alector Says Workforce Reduction Impacts About 75 Employees; Restructuring Charges Expected To Be About $7.7M
📉 NegativeBenzinga•Oct 21, 2025, 08:42 PM
Alector Discontinues Open-Label Extension For Latozinemab; Co To Reduce Workforce By About 49%
📉 NegativeBenzinga•Oct 21, 2025, 08:35 PM
Trading Halt: Halt status updated at 4:30:00 PM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Oct 21, 2025, 08:30 PM
Alector Reports In 96-Week, Double-Blind INFRONT-3 Trial, Latozinemab, Developed In Collaboration With GSK, Did Not Meet Clinical Co-Primary Endpoint Of Slowing FTD-GRN Progression
📉 NegativeBenzinga•Oct 21, 2025, 08:10 PM•Also:
Alector Reports Topline Results Latozinemab Phase 3 Trial In Individuals With Frontotemporal Dementia Due To GRN Mutation
➖ NeutralBenzinga•Oct 21, 2025, 08:08 PM
Trading Halt: Halted at 4:01:00 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Oct 21, 2025, 08:01 PM
BTIG Reiterates Buy on Alector, Maintains $5 Price Target
📈 PositiveBenzinga•Sep 25, 2025, 11:53 AM
Alector upgraded at Mizuho on high risk/higher-reward
📈 PositiveSeeking Alpha•Jul 28, 2025, 02:46 PM
Frequently Asked Questions about ALEC
What is ALEC's current stock price?
Alector, Inc. (ALEC) is currently trading at $1.40 per share. The stock has moved +0.72% today.
What is the analyst price target for ALEC?
The average analyst price target for ALEC is $3.25, based on 1 analyst.
What sector is Alector, Inc. in?
Alector, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ALEC's market cap?
Alector, Inc. has a market capitalization of $0.14 billion, making it a small-cap company.
Does ALEC pay dividends?
No, Alector, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABOS
Acumen Pharmaceuticals, Inc.
$2.15
Mkt Cap: $0.1B
APLT
Applied Therapeutics, Inc.
$0.13
Mkt Cap: $0.0B
CRBP
Corbus Pharmaceuticals Holdings, Inc.
$8.12
Mkt Cap: $0.1B
FATE
Fate Therapeutics, Inc.
$1.05
Mkt Cap: $0.1B
IRD
Opus Genetics, Inc.
$2.00
Mkt Cap: $0.1B
MOLN
Molecular Partners AG
$4.39
Mkt Cap: $0.2B
NKTX
Nkarta, Inc.
$1.79
Mkt Cap: $0.1B
PEPG
PepGen Inc.
$5.42
Mkt Cap: $0.4B
SAVA
Cassava Sciences, Inc.
$2.17
Mkt Cap: $0.1B
VOR
Vor Biopharma Inc.
$12.41
Mkt Cap: $0.1B
Explore stocks similar to ALEC for comparison